Clerk of the House of Representatives Legislative Resource Center B-106 Cannum Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE 99 AUG 16 PH 4: 18

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Registrant Narac Genentech, Inc.	•
	Suite 250 DC 20006 USA
Principal Place of Business (if different from line 2) City S. San Francisco State/Aip (or Country)	CA 94080 USA
4. Confact Name Telephone . E-mai Walter Moore	(optismal) 5. Schate ID # 15920-12
7. Client Name : Self Self	6. House iD 8 31464000
INCOME OR EXPENSES - Complete Either 12. Lobbying Firms	
Lobbying Firms Income relating to lobbying activities for this reporting	13. Organizations EXPENSES relating to lobbying activities for this reporting
period was:	period were:
Less than \$10,000 []	Less than \$10,000 (_)
\$10,000 or more >> \$	\$10,000 or more M >> \$ \$520,600.60 Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest	 REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.
F20,000 of all lobbying related income from the client including all payments to the registrant by any other entity	Method A. Reporting amounts using LDA definitions only
or lobbying activities on behalf of the client).	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
ignature	08/16/1999
ignature	Date 08/16/1999

Reg	istrant Name:	Geneatech, Inc.		
Clie	nt Name:	Self		
enga	aged in lobbyin	TIVITY. Select as many codes as necessary to reflect the general issue areas in which thing on behalf of the client during the reporting period. Using a separate page for each consistent Attach additional page(s) as needed.	e registrant ade, provide	
15.	General issue	e area code BUD (one per page)		
16,	2000, Title 6, S.1233, Agric	obying issues Agriculture, Rural Development, Food and Drug Administration, and Related Agent Agriculture, Rural Development, Food and Drug Administration, and Related Agencies iculture, Rural Development, Food and Drug Administration, and Related Agencies ovisions that relate to the FDA budget.		
17.		Congress and Federal agencies contacted Check if None cpresentatives		
l % ,	Name of each	ch individual who acted as a lobbyist in this issue area Covered Official Position (if applicable)		lew
	Moore, Walte	ker	N	(0
	Wagner, Heid		N	ŧο
		-		
19.	Interest of eac	i issues listed on line 16 above X Check if Non :	¢	
Siar	igiure	Date 08/16/199) 9	
		Walter Moore - Vice President, Government Affairs		e 10
£(33)	ted Name and I	1 Fixe	Page 2 o	f 10

Regis	trant Name:	Genentecb, Inc.	N
Client	Name:	Self	_
engag	ed in lobbyin	TIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrating on behalf of the client during the reporting period. Using a separate page for each code, prospected. Attach additional page(s) as needed.	
16. S	Specific Lobb H.R.1907, Ar	e area code <u>CPT</u> (one per page) blying issues American Enventors Protection Act of 1999, All provisions as they relate to reform of the pat edure (no specific legislation).	ent system.
 	Department o	Congress and Federal agencies contacted Check if None tof Commerce epresentatives	
18.	Name of each	th individual who acted as a lobbyist in this issue area	
1	Name	Covered Official Position (if applicable)	New
	Moore, Walt	ker	No
	Wagner, Hei	ridi	No
		ach foreign entity in the specific issues tisted on line 16 above	
Signa	dure	Date 08/16/1999	
Printe	ed Name and	Title Walter Moore - Vice President, Government Affairs	. Page 3 of 10

Regi	strant Name:	Genentech, Inc.	
Clier	nt Name:	<u>Self'</u>	
enga	iged in lobbyin	TIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant ag on behalf of the client during the reporting period. Using a separate page for each code, provide uested. Attach additional page(s) as neceded.	
15.	General issue	area code IICR (one per page)	
16.	H.R.1057, M H.R.1941, Ho H.R.306, Ger discriminatio H.R.448, Pate S.326, Patien S.543, Geneti discriminatio	incial Services Act of 1999, Provisions relating to medical confidentiality. ledical Information Privacy and Security Act, All provisions as they relate to medical records confidentiality, ledical Information Privacy Act, All provisions as they relate to medical records confidentiality, ledic Information Nondiscrimination in Health Insurance Act of 1999, All provisions as they relate to lient Protection Act of 1999, All provisions as they relate to genetic information discrimination. left of Rights Act, All provisions as they relate to genetic information discrimination, lie Information Nondiscrimination in Health Insurance Act of 1999, All provisions as they relate to genetic information.	genetic enetic
17.		Congress and Federal agencies contacted Check if None of Bealth & Human Services presentatives	
18.	Name of each	t individual who acted as a lobbyist in this issue area	
	Name	Covered Official Position (if applicable)	New
	Moore, Walis	er	No
	Wagner, Hei	di	No
19.	Interest of eac	ch foreign entity in the specific issues listed on line 16 above Check if None	
	Roche Holdir		
		Date <u>68/16/1999</u>	
Print	ted Name and '	Title Walter Moore - Vice President, Government Affairs Page 4	of 19

Registrant Name: Genenteck, Inc.

Client Name: Self

torn Description Data

Lobbying Issues S.578, Neutlth Care PIN Act, All provisions as they relate to medical records confidentiality.

Lobbying Issues S.881, Medical Information Protection Act of 1999, All provisions as they relate to medical records confidentiality.

Page 5 of 10

lient Name:			
	Self	<u>-</u> .	
gaged in tobbyi	- ,	y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.	
General issue	area code MMM (one per page)	1	
Medicare dr H.R.664, Pro- drug benefit S.731, Presci benefit.	eccess to Prescription Medications in Medications in Medications in Medications in Medications in Medications in Medications of the Seniors Act of Seniors Act of Seniors Act of	dicare Act of 1999, All provisions as they relate to the creat tof 1999, All provisions as they relate to the creation of a M 1999, All provisions as they relate to the creation of a Medi 1999, All provisions as they relate to the creation of a Medi	ledicare icare dru
	Congress and Federal agencies contacted presentatives	Check if None	
Name of eac	n individual who acted as a lobbyist in this	issue area Covered Official Position (if applicable)	New
Moore, Wal	ter		No
Wagner₁ He	idi		No
		!	
			<u> </u>
	ch foreign entity in the specific issues listeing Ltd None	at on line 16 above Check if Note	

Reg	istrant Name:	Genentech, Inc.		
Clie	nt Name:	Self		
enga	aged in lobbyin	IVITY. Select as many codes as necessary to reflect the get g on behalf of the client during the reporting period. Using tested. Attach additional page(s) as needed.		
15.	General issue	area code SCI (one per page)		
16.	Specific Lobb S.296, Pedera	rying issues if Research Investment Act, All provisions as they relate	to federal research investments.	
17.	House(s) of C House of Rep Sennte	ongress and Federal agencies contacted presentatives	☐ Check if None	
18.	Name of each	individual who acted as a lobbyist in this issue area Covered Officery	cial Position (if applicable)	New
	Moore, Walte	er .		No
	Wagner, Hei	di		No.
			- 4	
19.	interest of eac Roche Holdin	th foreign entity in the specific issues listed on line 16 above ng Ltd None	Check if None,	
			1	
			•	
Prin	ted Name and î	Fitle Walter Moore - Vice President, Government Affa	irs Page	7 of 10

Reg	istrant Name:	Genentech, Inc.		
Olite	nt Name:	Self		
nga	iged in lobbyín		y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.	
5.	General issue	area code TAX (one per page)		
16.	research exp medical inno H.R.760, To relate to the H.R.835, To atternative in credit. S.195, To am	o amend the Internal Revenue Code of I enses attributable to neadomic medical wation tax credit. amend the Internal Revenue Code of 19 extension of the research and developm amend the Internal Revenue Code of 19 icremental credit rates, All provisions a	186 to permanently extend the research credit and to adjust they relate to the extension of the research and develops to permanently extend the research credit, AB provisions	ons as they sl the sent tax
7.	House(s) of C House of Rep Senate	Congress and Federal agencies contacted presentatives	☐ Check if None	
18.	Name of each	i individual who acted as a lobbyist in this	issue area Covered Official Position (if applicable)	New
	Moore, Walt	er		No
	Wagner, Hei	dŧ		No
	-1.			
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	;		
9.	Interest of eac Ruche Holdi	ch foreign entity in the specific issues liste ng Ltd None	d on line 16 above □ Check if None	
Sign	ature	·	Date 08/16/1999	
_		Title Walter Moore - Vice President, C		8 of 19

Registrant Name: Genentech, Inc. Self Client Name: Data Rem Description 16 Lobbying Issues S.1010, To amend the Internal Revenue Code of 1986 to provide for a medical innovation tax credit for clinical testing research expenses attributable to academic medical centers and other qualified... All pravisions as they relate to the medical innovation tax credit. 16 Lobbying Issues S.680, To amond the Internal Revenue Code of 1986 to permanently extend the research credit, and for other purposes, All provisions as they relate to the extension of the research and development tax credit.

lient Name: Sel	<u>r</u>				
oformation Upd	ate Page - Complete ONLY where re	gistration information bas (	changed.		
0. Client new address					
I. Cisens new principal	place of business (if different from line 20)				
City	State/Zip (or Country)				
2. New general descript	ion of client's business or activities				
LOBBYIST UPDA	TE				
	rviously reported individual who is no lon-	ger expected to act as a lobby	vist for the client		
SSUE UPDATE					
	issues previously reported that no longer	pertain			
GOV, MAN					
EDILLATED OD	C1 2 WYPCH A 1909 JUNE 20				
FFILIATED OR: 5. Add the followin	g affiliated organization(s)				
Na	me } Ad	Address		Principal Place of Business (city and state or country)	
	}				
6. Name of each pre	eviously reported organization that is no to	nger affiliated with the regis	trant of client		
6. Name of each pre	eviously reported organization that is no to	nger affiliated with the regis	trant or client		
6. Name of each pro	eviously reported organization that is no to	nger affiliated with the regis	tram or client		
FOREIGN ENTIT	IES	nger affiliated with the regis	trant or client		
FOREIGN ENTIT	IES	YII.A.L.	······	Ownczskie 9	
FOREIGN ENTIF 17. Add the followin Name	IES	nger affiliated with the regis  Principal Place of Business (city and state or country)	Amount of contribution for fobbying activities	Ownceship %	
POREIGN ENTIT 17. Add the followin Name	IES g foreign entities  Address c/o F. Hoffmann La Roche AG	Principal Place of Business	Amount of contribution	1	
POREIGN ENTIT 7. Add the followin Name	IES g foreign entities Address	Principal Place of Business	Amount of contribution for foobying activities	in client	
FOREIGN ENTIT 7. Add the followin	Address  Address  c/o F. Hoffmann La Roche AG  Basel Cli-1002 Switzerland	Principal Place of Business (city and state or country)	Amount of contribution for tobbying activities \$0.00	in client	
FOREIGN ENTIT 27. Add the followin Name oche Holding Ltd	Address  c/o F. Hoffmann La Roche AG  Basel Cll-1002 Switzerland	Principal Place of Business (city and state or country)	Amount of contribution for tobbying activities \$6.00	in client 81.00%	
POREIGN ENTIT 17. Add the followin  Name sche Holding Ltd  18. Name of each pre or affiliated organ	Address  C/o F. Hoffmann La Roche AG  Basel CH-1002 Switzerland  Eviously reported foreign entity that so ton	Principal Place of Business (city and state or country)	Amount of contribution for tobbying activities \$6.00	in client 81.00%	
FOREIGN ENTIT 27. Add the followin Name oche Holding Ltd	Address  C/o F. Hoffmann La Roche AG  Basel CH-1002 Switzerland  Eviously reported foreign entity that so ton	Principal Place of Business (city and state or country)	Amount of contribution for tobbying activities \$6.00	in client 81.00%	
FOREIGN ENTIT 27. Add the followin  Name sche Holding Ltd  28. Name of each pre or affiliated organ	Address  Address  c/o F. Hoffmann La Roche AG  Basel CH-1002 Switzerland  eviously reported foreign entity that so ion nization	Principal Place of Business (city and state or country)	Amount of contribution for tobbying activities \$6.00	in client 81.00%	